GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
1.4k
c/glp1science·posted 8 months ago by u/marisol_kravchenko

receptor is the most under-discussed thing on this board

Speculation Slow Clap ×3 Well Actually ×2

Posting this as a discussion rather than a claim: receptor is the most under-discussed thing on this board.

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.

Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.

1,569 up / 205 down88% upvoted60 commentsid yhf9rr10 Nov 2025

60 comments

30 in this archive, depth 6

best — the order this archive was captured in

u/gastric_emptying_gMOD133 points·8 months ago

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

replysharereportpermalink
u/kian_balogun106 points·8 months ago

Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.

replysharereportpermalink
[removed]76 points·8 months ago

[removed by moderator]

replysharereportpermalink
u/camila_kowalski65 points·8 months ago

Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.

replysharereportpermalink
u/marisol_kravchenkoOP106 points·8 months ago

Correcting my own comment: I attributed that to the GIP arm and the paper attributes it to the GLP-1 arm.

replysharereportpermalink
u/formulary_fighterappeals30 points·8 months ago

That study was in a rodent model. Worth stating, since the thread has been reading it as human data.

replysharereportpermalink
u/whois_wanda35 points·8 months ago

mechanism explains a direction, not a magnitude

replysharereportpermalink
u/marisol_kravchenko65 points·8 months ago

Does the effect persist with continued dosing or does tolerance develop?

replysharereportpermalink
u/tomas_lundgren-20 points·8 months ago

receptor agonism is not the same as receptor activation in every tissue

replysharereportpermalink
u/sig_figs_sammod · analytical1 point·8 months ago

half-life is why these are weekly and not daily

replysharereportpermalink
u/rasmus_kimani53 points·8 months ago

the peripheral and central stories are not in competition

replysharereportpermalink
u/flair_enthusiast35 points·8 months ago

That conflates receptor affinity with clinical potency. They are related and they are not the same thing.

replysharereportpermalink
u/the_poster_in_question_202613 points·8 months ago

Right — mechanism gives you a direction. It never gives you an effect size and people use it as though it does.

replysharereportpermalink
u/ilias_kaufmann15 points·8 months ago

gastric emptying slows, it does not stop

replysharereportpermalink
u/nadia_bakker93 points·8 months ago·edited

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

replysharereportpermalink
u/marisol_kravchenkoOP36 points·8 months ago

Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.

replysharereportpermalink
u/ismael_chukwu23 points·8 months ago

Is that from a human study or a preclinical model?

replysharereportpermalink
u/yusuf_ramos7 points·8 months ago

albumin binding is most of the half-life story

replysharereportpermalink
u/formulary_fighterappeals48 points·8 months ago·edited

Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.

replysharereportpermalink
u/hassan_castellanos28 points·8 months ago·edited

Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.

formulary_fighter is right that mechanism gives direction and not magnitude. Worth pinning.

replysharereportpermalink
u/rasmus_kimani0 points·8 months ago

formulary_fighter is right that mechanism gives direction and not magnitude.

This is the concept everything else on this board is downstream of.

replysharereportpermalink
u/anya_salgado40 points·8 months ago

GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.

replysharereportpermalink
u/trialwatch_theotrial nerd14 points·8 months ago

This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.

replysharereportpermalink
u/plain_titration8 points·8 months ago

Yes. The central component is the one that explains the reports on this site better than gastric emptying does.

replysharereportpermalink
u/employer_carveout2 points·8 months ago

a mechanism you can state is not a mechanism you have demonstrated

replysharereportpermalink
u/marisol_kravchenko1 point·8 months ago

tolerance to the gastric effect develops, appetite effect largely persists

replysharereportpermalink
u/split_dose_sceptic14 points·8 months ago

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

replysharereportpermalink
u/rafael_ostergaard10 points·8 months ago

Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.

replysharereportpermalink
u/devils_advocate_d2 points·8 months ago

preclinical is not clinical and rodents are not small people

replysharereportpermalink
u/emeka_chowdhury4 points·8 months ago

the central appetite effect is doing more work than the gut effect

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.